New Implantable System Uses Electrocatalysis to Manage Blood Glucose in Preclinical Trials

Researchers at ETH Zurich have developed an experimental implantable system designed to regulate blood sugar levels and reduce weight using an inorganic catalyst rather than biological components. Led by Professor Martin Fussenegger, the team published their findings in the journal Science, detailing a wireless, electronically controlled approach intended to address the underlying energy surplus associated with type 2 diabetes.

Moving Away From Biological Components

Traditional treatments for type 2 diabetes, such as insulin injections, help muscle cells take up glucose from the bloodstream, but they do not eliminate excess energy. If that energy is not physically expended, the body typically converts it into fat, which explains why many patients continue to gain weight despite standard interventions. Furthermore, earlier experimental attempts to regulate blood sugar using biological systems faced significant hurdles concerning immune tolerance, long-term stability, manufacturing, and regulatory approvals.

To bypass these biological complications, the ETH Zurich research team engineered a system composed entirely of inorganic materials. The catalyst consists of graphite felt studded with gold nanoclusters decorated with microscopic platinum particles. According to the study authors, these materials demonstrated high biocompatibility during the experimental phase.

How the Wireless Electrocatalytic System Operates

The experimental device features a specialized catalyst housed alongside an electronic control unit in a 3D-printed casing. Power is supplied wirelessly at a frequency of 13.56 MHz, which is standard for industrial, scientific, and medical applications. The catalyst functions by converting excess glucose in the bloodstream into gluconate, which is subsequently excreted through urine rather than being stored in tissue as fat.

The implant operates via a closed-loop wireless network. A standard continuous glucose monitor, similar to those worn on the upper arm by many people managing diabetes, tracks tissue sugar levels in real time. When glucose spikes following a meal, the sensor transmits a Bluetooth signal to a smartphone or smartwatch, which then activates the implant’s catalyst. Once blood sugar returns to the target range, the device automatically shuts off to protect against hypoglycemia.

Preclinical Findings and Limitations

In laboratory testing, the researchers evaluated the system within a five-liter nutrient solution reservoir, which roughly approximates the total blood volume of an adult human. The tests demonstrated that the catalyst could successfully process glucose within that volume.

The system was also tested in diabetic mice over a six-week duration. Researchers observed that the animals experienced precise blood sugar regulation and subsequent weight loss. The implant was reported to be well tolerated, operating reliably without causing any observable thermal or electrical tissue damage.

However, the study authors emphasize significant limitations. The device has not yet been tested in human clinical trials. While the underlying components utilize commercially available technology and established wireless power transmission methods, translating the device into a validated clinical tool will require extensive further research and regulatory evaluation.

Potential Implications for Diabetes Care

Professor Fussenegger characterizes the technology as a potential conceptual shift in managing metabolic conditions, moving away from pharmaceutical interventions toward digital, electronically controlled environments linked to the Internet of Things. Because the core glucose-converting mechanism operates independently of living cells or complex enzymes, the researchers suggest that technical development could proceed more directly than previous cell-based therapies. Further investigations will be necessary to determine whether these preclinical results can be safely and effectively replicated in human patients.

• Experimental implant converts excess blood glucose into gluconate using an inorganic catalyst
• System utilizes a closed-loop network connected to standard continuous glucose monitors and smart devices
• Preclinical testing in mice showed successful blood sugar regulation and weight reduction over a six-week period